Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Selecta Biosciences doses first patient in phase II trial of SEL-212

Oct. 27, 2016

Lexicon Pharmaceuticals reports positive results for phase II trial of sotagliflozin

Oct. 27, 2016

FDA grants fast track designation to ABO-102 for MPS IIIA

Oct. 26, 2016

Alphamab starts phase I trial of KN-015

Oct. 26, 2016

Investigators identify novel mutations in Pompe disease

Oct. 25, 2016

New mutations in known disease-associated genes

Oct. 24, 2016

ProMetic Life Sciences reports results from phase II study of PBI-4050

Oct. 21, 2016

Ionis Pharmaceuticals presents promising clinical data for IONIS-APO(a)Rx and IONIS-APO(a)-LRx

Oct. 21, 2016

SOBI-003 granted European orphan drug status

Oct. 21, 2016

Perlara forms drug discovery collaboration with Novartis

Oct. 20, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...